- Acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company.
- The team has over 65 years of experience in the testing and analytics space and a full-time staff of nine employees including, two Ph.D. analytical chemists and five other scientists.
- A recent report from Coherent Market Insights1 estimates that the global cannabis testing market is projected to grow 13.2% year-over-year through 2026, when it is expected to surpass $1.5 billion USD.
- Applied BioSciences products use base ingredients that are USDA Organic and non-GMO. Offering Vegan, sugar-free, 99% Pure CBD Isolate infused. The products are formulated with CBD extracted from pesticide-free, organically grown, domestically produced, High-CBD Industrial Hemp. Lab-tested and guaranteed Pesticide and Chemical-free. Our proprietary blends also contain USDA certified organic botanicals, herbals and essential oils to provide synergy with other healing elements found in nature.
- On December 20, 2018, President Trump signed the US Farm Bill into law. The new law defines hemp as an agricultural product for the first time in 50 years and allows American farmers to plant and harvest hemp. This will allow farmers and researchers of hemp to receive the same benefits as farmers and researchers of other crops, including the ability to apply for insurance and federal grants
- Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00
FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp.
Tags: #APPB, #AppliedBiosciences, #Remedi, #TraceAnalytics, Cannabis, CBD